Terran

Group of Concerned Investors in Terran Orbital Call For Immediate Separation of Chairman and CEO Roles at Company and Installation of New Highly Qualified CEO

Retrieved on: 
Tuesday, December 12, 2023
Professional Services, Technology, Satellite, Aerospace, Manufacturing, Finance, Sale, NYSE, Security (finance), Finastra, AGC Aerospace & Defense, The Wall Street Journal, Jefferies, Defense, Bell, TechCrunch, Letter, Concerned, Reinsurance, Management, Terran

“Accordingly, we reiterate our call for Terran’s Board to immediately separate the role of CEO and Chairman and install a new CEO with demonstrable industry experience and a track record of outperformance, who can turn around the operational, cultural, and capital allocation issues plaguing the Company. We believe that a new CEO, namely our identified CEO candidate--who, for the avoidance of doubt is not a former employee of the Company—will help Terran to attract the needed capital on favorable terms, minimizing future dilution to stockholders and providing prospective customers and employees with the confidence to conduct business with the Company going forward. In addition, we believe, if installed, our CEO candidate would attract and retain additional world class talent. Mr. Bell has also stated publicly that Jefferies is ‘exploring all possibilities,’ though this cannot be true without engaging with our CEO candidate and the Concerned Investor Group.

Key Points: 
  • However, the events over the past 24 hours have made it abundantly clear to us that Marc Bell is not fit to be CEO of Terran.
  • Later that day, in an all-employee meeting, Mr. Bell stated, as reported by TechCrunch, that the Company was indeed not for sale.
  • Mr. Bell has also stated publicly that Jefferies is ‘exploring all possibilities,’ though this cannot be true without engaging with our CEO candidate and the Concerned Investor Group.
  • The company recently sued one of the Sophis idiots and we will be suing them all in due course.

Terran Biosciences Receives Notice of Allowance for Four US Patents Including for the World’s First New Salts and Polymorphs of Psilocybin, potentially enabling future 505(b)(2) pathway

Retrieved on: 
Friday, December 8, 2023
Men, Research, Other Health, Pharmaceutical, Consumer, Mental Health, Clinical Trials, Science, Biotechnology, Alternative Medicine, FDA, Health, Other Science, Psilocybin, Vomiting, MAOI, Depression, Safety, GMP, Chemistry, DMT, Patient, Therapy, Nausea, Hydrogen chloride, Patent, Blood pressure, Pharmaceutical industry, Terran

Two of these patents cover the world’s first new forms of psilocybin (psilocybin HCl and psilocybin edisylate) and their method of use in treating neurological and psychiatric disorders, including depression.

Key Points: 
  • Two of these patents cover the world’s first new forms of psilocybin (psilocybin HCl and psilocybin edisylate) and their method of use in treating neurological and psychiatric disorders, including depression.
  • The clinical trials of psilocybin to date have been limited to using the older forms of zwitterionic psilocybin described in the historical literature.
  • Terran plans to use its new forms of psilocybin to pursue a rapid 505(b)(2) FDA approval pathway if one of the existing forms of psilocybin currently in clinical trials is approved.
  • Terran believes this new discovery may be the most stable form of tabernanthalog monofumarate.

Group of Concerned Co-founders and Investors in Terran Orbital Sends Letter to Board

Retrieved on: 
Thursday, November 9, 2023
Professional Services, Technology, Satellite, Aerospace, Manufacturing, Finance, Suite, Publishing, NYSE, LLAP, Lockheed Martin, Multimedia, Enclosure, Sustainability Accounting Standards Board, Prospectus, Risk, Attitude, Travel, Tranche, Letter, Management, Pharmaceutical industry, Terran

We believe such a stance only further erodes shareholder value and market confidence in Terran.

Key Points: 
  • We believe such a stance only further erodes shareholder value and market confidence in Terran.
  • Our primary concern remains protecting and ultimately enhancing the value that we believe is embedded in Terran, to the benefit of all shareholders.
  • We continue to offer solutions that, in our view, are the best hope for sustainably reversing sentiment and performance at Terran.
  • Olshan Frome Wolosky LLP is serving as legal counsel to the Concerned Investor Group.

Terran Biosciences CEO to Deliver Keynote Speech at Microdose's 3rd Annual Wonderland Conference

Retrieved on: 
Thursday, November 2, 2023
Microdosing, Longevity, Ageing, Neuroregeneration, Therapy, Human, MD, Conference, Doctor of Philosophy, Brain, Keynote, Rejuvenation, Terran

New York, New York--(Newsfile Corp. - November 2, 2023) - Terran Biosciences , a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, today announced that Terran's founder and CEO, Sam Clark, MD, PhD, will be delivering a keynote address at Microdose's 3rd Annual Wonderland Conference in Miami, Florida, November 9th.

Key Points: 
  • New York, New York--(Newsfile Corp. - November 2, 2023) - Terran Biosciences , a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, today announced that Terran's founder and CEO, Sam Clark, MD, PhD, will be delivering a keynote address at Microdose's 3rd Annual Wonderland Conference in Miami, Florida, November 9th.
  • Terran Biosciences CEO Sam Clark, MD, PhD
    To view an enhanced version of this graphic, please visit:
    "Our mission is rooted in creating a future that includes treating aging-related diseases through enhanced brain function and rejuvenation," said Dr. Clark.
  • This will be the first presentation of imaging data in humans supporting that the effects of a psychedelic on global brain connectivity and functional neuronal connectivity occur in the absence of a perceptual trip.
  • In addition to presenting the Keynote, Dr. Clark will lead a workshop, and will be speaking on two panels:

Group of Concerned Co-Founders and Investors in Terran Orbital Send Letter to Board Outlining Immediate Actions Required to Protect and Maximize Stockholder Value

Retrieved on: 
Thursday, October 12, 2023
Professional Services, Technology, Satellite, Aerospace, Manufacturing, Finance, Institutional Shareholder Services, NYSE, Audit committee, Compensated emancipation, Letter, Government, Enterprise value, Rationalization, Culture, Defense, LLAP, Entrepreneurship, EAC, Enterprise, Weakness, Lockheed Martin, Board for Licensing Matters and Foreign Medical Practitioners, Professional Football Compensation Committee, Suite, Evaluation, Sale, AGC Aerospace & Defense, Management, Retail, Security (finance), Lockheed, Terran, Tyvak

Commence a comprehensive strategic review process and retain outside financial and legal advisors to evaluate all strategic alternatives and opportunities available to maximize stockholder value.

Key Points: 
  • Commence a comprehensive strategic review process and retain outside financial and legal advisors to evaluate all strategic alternatives and opportunities available to maximize stockholder value.
  • We write to you as aligned, long-term stockholders and experienced Aerospace & Defense investors seeking a constructive dialogue to protect and maximize the material value we believe is embedded within Terran.
  • We believe that Terran has several potential strategic opportunities available to maximize value for stockholders and other stakeholders.
  • We are highly confident that doing so will maximize long-term value for Terran and is in the best interests of the Company’s stockholders, employees, and customers.

Relativity Space Signs Lease on Historic NASA Test Stand

Retrieved on: 
Thursday, September 7, 2023
Engineering, Technology, Satellite, Aerospace, Manufacturing, Hardware, Constellation, Saturn V, Partnership, Rejuvenation, Space Shuttle program, Apollo program, E-4, Albert Einstein's brain, Space Shuttle, 3D, E-2, Multimedia, Research, Tenant, EULA, Saturn, NASA, Entrepreneurship, Constellation program, Relativity Space, E-1, Terran, John C. Stennis, Stennis Space Center, Communications satellite, Gulf Coast of the United States, Relativity

Relativity Space , the preeminent 3D printed rocket company, has signed an enhanced use lease agreement (EULA) on the vertical test stand at the A-2 complex within NASA’s historic Stennis Space Center in Hancock County, Mississippi.

Key Points: 
  • Relativity Space , the preeminent 3D printed rocket company, has signed an enhanced use lease agreement (EULA) on the vertical test stand at the A-2 complex within NASA’s historic Stennis Space Center in Hancock County, Mississippi.
  • View the full release here: https://www.businesswire.com/news/home/20230907155639/en/
    A rendering of Terran R's first stage on the A-2 Test Stand at NASA's Stennis Space Center (Graphic: Business Wire)
    Established in the 1960s, NASA Stennis is the nation’s largest and most prestigious propulsion test center.
  • “New history is being written at Stennis Space Center as we breathe life into the historic A-2 Test Stand with our Terran R program,” said Tim Ellis, Co-Founder and CEO of Relativity Space.
  • I appreciate the partnership of companies like Relativity Space who are helping Mississippi stay at the leading edge.”
    “The A-2 test stand at Stennis Space Center has a long and storied history as part of the U.S. space program, and the agreement with Relativity Space will extend that record,” said Senator Cindy Hyde-Smith.

Terran Biosciences announces exclusive licensing deal with Pierre Fabre for idazoxan; Terran completes key development milestones

Retrieved on: 
Friday, June 2, 2023
Drug Master File, Pierre Fabre, Half-life, Schizophrenia, Idazoxan, CMC, Clinical trial, Pharmacokinetics, DSM-IV codes, CNS, Plasma, Patient, XR, FDA, S.A.S, Safety, Pharmaceutical industry, Terran

The deal features the novel lead compound idazoxan, a selective alpha 2 receptor antagonist, along with a portfolio of other compounds with a similar mechanism of action.

Key Points: 
  • The deal features the novel lead compound idazoxan, a selective alpha 2 receptor antagonist, along with a portfolio of other compounds with a similar mechanism of action.
  • Idazoxan has been tested in multiple phase 3 clinical studies and has been dosed in over 1,000 patients across a variety of neuropsychiatric indications.
  • Dr. Sam Clark, Terran's founder and CEO remarked, "We are thrilled to partner with the team at Pierre Fabre and to push forward with the development of idazoxan and this pipeline of CNS compounds.
  • Given the strength of the human data to date, we believe idazoxan XR has the potential to revolutionize the treatment of patients with schizophrenia and other neuropsychiatric disorders."

Terran Biosciences announces new breakthroughs in the chemistry of MDMA and its enantiomers and analogs, discovers new salts and polymorphs, publishes PCT application.

Retrieved on: 
Friday, May 26, 2023
MDAI, Therapy, MEAI, PTSD, PCT, MDE, Literature, Patent, Post-traumatic stress disorder, Patient, USE, MBDB, Empathy, Terran, SALTS, MDMA, MDEA, Pharmaceutical industry

MDMA is the most studied empathogen to date and has been shown to be an effective treatment for post-traumatic stress disorder (PTSD) in multiple phase 3 trials.

Key Points: 
  • MDMA is the most studied empathogen to date and has been shown to be an effective treatment for post-traumatic stress disorder (PTSD) in multiple phase 3 trials.
  • Historically, MDMA has only been developed as a single salt and the crystal structures of its enantiomers had not been characterized.
  • As previously reported, Terran found that the S enantiomer of MDEA had significant advantages over the (R)-MDEA in preclinical models.
  • Terran is also developing the S enantiomer of MBDB which was shown to have significant advantages over (R)-MBDB in preclinical models.

Terran Biosciences discovers what may be the first new salts, co-crystals, and polymorphs of psilocybin in history, publishes PCT patent application, and files psilocybin Drug Master File (DMF) with FDA

Retrieved on: 
Friday, May 19, 2023
Psilocybin, GMP, Human, Drug Master File, Depression, Therapy, SOLID, History, PCT, Literature, Hydrogen chloride, Patent, Patient, DMF, Ecosystem, Salt, FDA, Terran, SALTS, Pharmaceutical industry

Psilocybin is one of the main active compounds in psychedelic mushrooms and has been used by humans for thousands of years.

Key Points: 
  • Psilocybin is one of the main active compounds in psychedelic mushrooms and has been used by humans for thousands of years.
  • Recent clinical studies suggest psilocybin is efficacious in treating depression.
  • According to the literature, there are three main polymorphic forms of zwitterionic psilocybin: form A, form B, and form A' (A-Prime).
  • Terran also replicated this comprehensive set of studies with the psilocin prodrug O-acetylpsilocin, resulting in additional novel salts and polymorphs of that compound as well.

Another Record: Terran Orbital-Developed PTD-3 Enables 200 Gigabits per Second Space-to-Ground Optical Link

Retrieved on: 
Friday, May 12, 2023
Satellite, Technology, Aerospace, Manufacturing, Other Technology, Software, Hardware, Orbital, Multimedia, MIT Lincoln Laboratory, Second, Space Communications and Navigation Program, NASA, LLAP, TBIRD, Terran, Byte, NYSE, Orbital Corporation, Communications satellite, Navigation

Terran Orbital Corporation (NYSE: LLAP ), (“Terran Orbital” or “the Company”), a global leader in satellite-based solutions primarily serving the aerospace and defense industries, today announced the Terran Orbital-developed Pathfinder Technology Demonstrator 3 (PTD-3) satellite enabled a successful 200 gigabits per second space-to-ground optical link.

Key Points: 
  • Terran Orbital Corporation (NYSE: LLAP ), (“Terran Orbital” or “the Company”), a global leader in satellite-based solutions primarily serving the aerospace and defense industries, today announced the Terran Orbital-developed Pathfinder Technology Demonstrator 3 (PTD-3) satellite enabled a successful 200 gigabits per second space-to-ground optical link.
  • View the full release here: https://www.businesswire.com/news/home/20230512005082/en/
    Terran Orbital-Developed PTD-3 Enables 200 Gigabits per Second Space-to-Ground Optical Link (Image Credit: NASA)
    With a transmission rate of multiple orders of magnitude faster than current state-of-the-art satellite communications, this technology enables spacecraft to downlink several terabytes of data to the ground in a single ground station pass.
  • The 200 gigabits per second space-to-ground optical link broke this record.
  • “The completion of the 200 gigabits per second link is both monumental and record-breaking,” said Terran Orbital Co-Founder, Chairman, and Chief Executive Officer Marc Bell.